Francesca Toselli

Francesca Toselli

Auto-generated profile, based on publicly available information

Francesca Toselli

Johnson & Johnson, Turnhoutseweg 30, 2340, Beerse, Belgium

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2015 in Drug Metabolism and Disposition
Verified
Journal Article
Open access
PDF file
IDIris M. Booth Depaz
Iris M. Booth Depaz
FTFrancesca Toselli
Francesca Toselli
PWPeter A Wilce
Peter A Wilce
EGElizabeth M. J. Gillam
Elizabeth M. J. Gillam
Cytochrome P450 enzymes from the CYP2C subfamily play a prominent role in the metabolic clearance of many drugs. CYP2C enzymes have also been implicated in the metabolism of arachidonic acid to vasoactive epoxyeicosatrienoic acids. CYP2C8, CYP2C9, and CYP2C19 are expressed in the adult liver at significant levels; however, the expression of CYP2C enzymes in extrahepatic tissues such as the brain is less well characterized. Form-specific antibodies to CYP2C9 and CYP2C19 were prepared by affinity purification of antibodies raised to unique peptides. CYP2C9 and CYP2C19 were located in microsomal fractions of all five human brain regions examined, namely the frontal cortex, hippocampus, basal ganglia, amygdala, and cerebellum. Both CYP2C9 and CYP2C19 were detected predominantly within the neuronal soma but with expression extending down axons and dendrites in certain regions. Finally, a comparison of cortex samples from alcoholics and age-matched controls suggested that CYP2C9 expression was increased in alcoholics.

20 June 2016 in Drug Metabolism Reviews
Verified
Journal Article
Closed access
FTFrancesca Toselli
Francesca Toselli
PDPeter R. Dodd
Peter R. Dodd
EGElizabeth M. J. Gillam
Elizabeth M. J. Gillam
P450s in the human brain were originally considered unlikely to contribute significantly to the clearance of drugs and other xenobiotic chemicals, since their overall expression was a small fraction of that found in the liver. However, it is now recognized that P450s play substantial roles in the metabolism of both exogenous and endogenous chemicals in the brain, but in a highly cell type- and region-specific manner, in line with the greater functional heterogeneity of the brain compared to the liver. Studies of brain P450 expression and the characterization of the catalytic activity of specific forms expressed as recombinant enzymes have suggested possible roles for xenobiotic-metabolizing P450s in the brain. It is now possible to confirm these roles through the use of intracerebroventricular administration of selective P450 inhibitors in animal models, coupled with brain sampling techniques to measure drug concentrations in vivo, and modern neuroimaging techniques. The purpose of this review is to discuss the evidence behind the functional importance of P450s from the "xenobiotic-metabolizing" families, CYP1, CYP2 and CYP3 in the brain. Approaches used to define the quantitative and qualitative significance of these P450s in determining tissue-specific levels of xenobiotics in brain will be considered. Finally, the possible roles of these enzymes in brain biochemistry will be examined in light of the demonstrated activity of these enzymes in vitro and the association of particular P450 forms with disease states.

1 July 2009 in Life Sciences
Verified
Journal Article
Closed access
FTFrancesca Toselli
Francesca Toselli
AMAnita Matthias
Anita Matthias
EGElizabeth M.J. Gillam
Elizabeth M.J. Gillam

1 August 2017 in Drug Metabolism and Disposition
Verified
Journal Article
Open access
PDF file
FTFrancesca Toselli
Francesca Toselli
MFMarlene Fredenwall
Marlene Fredenwall
PSPeder Svensson
Peder Svensson
XLXueqing Li
Xueqing Li
AJAnders Johansson
Anders Johansson
MHMartin Allistair Hayes
Martin Allistair Hayes
Oxetanyl building blocks are increasingly used in drug discovery because of the improved drug-like properties they confer on drug candidates, yet little is currently known about their biotransformation. A series of oxetane-containing analogs was studied and we provide the first direct evidence of oxetane hydrolysis by human recombinant microsomal epoxide hydrolase (mEH). Incubations with human liver fractions and hepatocytes were performed with and without inhibitors of cytochrome P450 (P450), mEH and soluble epoxide hydrolase (sEH). Reaction dependence on NADPH was investigated in subcellular fractions. A full kinetic characterization of oxetane hydrolysis is presented, in both human liver microsomes and human recombinant mEH. In human liver fractions and hepatocytes, hydrolysis by mEH was the only oxetane ring-opening metabolic route, with no contribution from sEH or from cytochrome P450-catalyzed oxidation. Minimally altering the structural elements in the immediate vicinity of the oxetane can greatly modulate the efficiency of hydrolytic ring cleavage. In particular, higher pKa in the vicinity of the oxetane and an increased distance between the oxetane ring and the benzylic nitrogen improve reaction rate, which is further enhanced by the presence of methyl groups near or on the oxetane. This work defines oxetanes as the first nonepoxide class of substrates for human mEH, which was previously known to catalyze the hydrolytic ring opening of electrophilic and potentially toxic epoxide-containing drugs, drug metabolites, and exogenous organochemicals. These findings will be of value for the development of biologically active oxetanes and may be exploited for the biocatalytic generation of enantiomerically pure oxetanes and diols.

1 June 2013 in Drug Metabolism and Disposition
Verified
Journal Article
Closed access
PDF file
IDIris M. Booth Depaz
Iris M. Booth Depaz
FTFrancesca Toselli
Francesca Toselli
PWPeter A Wilce
Peter A Wilce
EGElizabeth M. J. Gillam
Elizabeth M. J. Gillam
Cytochrome P450 enzymes are responsible for the metabolism of most commonly used drugs. Among these enzymes, CYP3A forms mediate the clearance of around 40–50% of drugs and may also play roles in the biotransformation of endogenous compounds. CYP3A forms are expressed both in the liver and extrahepatically. However, little is known about the expression of CYP3A proteins in specific regions of the human brain. In this study, form-selective antibodies raised to CYP3A4 and CYP3A5 were used to characterize the expression of these forms in the human brain. Both CYP3A4 and CYP3A5 immunoreactivity were found to varying extents in the microsomal fractions of cortex, hippocampus, basal ganglia, amygdala, and cerebellum. However, only CYP3A4 expression was observed in the mitochondrial fractions of these brain regions. N-terminal sequencing confirmed the principal antigen detected by the anti-CYP3A4 antibody in cortical microsomes to be CYP3A4. Immunohistochemical analysis revealed that CYP3A4 and CYP3A5 expression was primarily localized in the soma and axonal hillock of neurons and varied according to cell type and cell layer within brain regions. Finally, analysis of the frontal cortex of chronic alcohol abusers revealed elevated expression of CYP3A4 in microsomal but not mitochondrial fractions; CYP3A5 expression was unchanged. The site-specific expression of CYP3A4 and CYP3A5 in the human brain may have implications for the role of these enzymes in both normal brain physiology and the response to drugs.

14 April 2015 in Alcohol, Clinical and Experimental Research
Verified
Journal Article
Closed access
PDF file
FTFrancesca Toselli
Francesca Toselli
IDIris M. Booth Depaz
Iris M. Booth Depaz
SWSimon Worrall
Simon Worrall
NENaomi Etheridge
Naomi Etheridge
PDPeter R. Dodd
Peter R. Dodd
EGElizabeth M. J. Gillam
Elizabeth M. J. Gillam